252 related articles for article (PubMed ID: 24442759)
1. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.
Devecı H; Kobak S
Int Ophthalmol; 2014 Oct; 34(5):1043-8. PubMed ID: 24442759
[TBL] [Abstract][Full Text] [Related]
2. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren's Syndrome.
Gao M; Zhao L; Liang R; Zhu Q; Zhao Q; Kong X
Ocul Immunol Inflamm; 2023 Oct; 31(8):1662-1668. PubMed ID: 35914303
[TBL] [Abstract][Full Text] [Related]
4. [Current treatments of xerophthalmia in Sjögren's syndrome].
Baudouin C; Pisella PJ; Brignole F
Rev Med Interne; 2004 May; 25(5):376-82. PubMed ID: 15110955
[TBL] [Abstract][Full Text] [Related]
5. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
6. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.
Cubuk MO; Ucgul AY; Ozgur A; Ozulken K; Yuksel E
Int Ophthalmol; 2021 Apr; 41(4):1479-1485. PubMed ID: 33484384
[TBL] [Abstract][Full Text] [Related]
7. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.
Moawad P; Shamma R; Hassanein D; Ragab G; El Zawahry O
Eur J Ophthalmol; 2022 Jan; 32(1):673-679. PubMed ID: 33530719
[TBL] [Abstract][Full Text] [Related]
10. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome.
Gündüz K; Ozdemir O
Acta Ophthalmol (Copenh); 1994 Aug; 72(4):438-42. PubMed ID: 7825408
[TBL] [Abstract][Full Text] [Related]
11. The Potential Role for Early Biomarker Testing as Part of a Modern, Multidisciplinary Approach to Sjögren's Syndrome Diagnosis.
Beckman KA; Luchs J; Milner MS; Ambrus JL
Adv Ther; 2017 Apr; 34(4):799-812. PubMed ID: 28283891
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
[No Abstract] [Full Text] [Related]
13. Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren's Syndrome Dry Eye.
Kang MJ; Kim YH; Chou M; Hwang J; Cheon EJ; Lee HJ; Chung SH
Ocul Immunol Inflamm; 2020 Apr; 28(3):370-378. PubMed ID: 30986119
[No Abstract] [Full Text] [Related]
14. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome.
Hong S; Kim T; Chung SH; Kim EK; Seo KY
J Ocul Pharmacol Ther; 2007 Feb; 23(1):78-82. PubMed ID: 17341155
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review.
Akpek EK; Lindsley KB; Adyanthaya RS; Swamy R; Baer AN; McDonnell PJ
Ophthalmology; 2011 Jul; 118(7):1242-52. PubMed ID: 21459453
[TBL] [Abstract][Full Text] [Related]
16. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
17. [Flow cytometry in impression cytology during keratoconjunctivitis sicca: effects of topical cyclosporin A on HLA DR expression].
Galatoire O; Baudouin C; Pisella PJ; Brignole F
J Fr Ophtalmol; 2003 Apr; 26(4):337-43. PubMed ID: 12843889
[TBL] [Abstract][Full Text] [Related]
18. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
19. High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen.
Dastjerdi MH; Hamrah P; Dana R
Cornea; 2009 Dec; 28(10):1091-6. PubMed ID: 19770713
[TBL] [Abstract][Full Text] [Related]
20. Unexplained cough: it is time to rule out Sjogren's syndrome.
Koslow M; Kivity S; Vishnevskia-Dai V; Ben-Dov I
Clin Rheumatol; 2018 May; 37(5):1215-1222. PubMed ID: 29388084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
